Deletions of chromosome 22ql 1 have been seen in association with DiGeorge syndrome (DGS) and velocardiofacial syndrome (VCFS). In the present study, we analysed samples from 76 patients referred with a diagnosis of either DGS or VCFS to determine the prevalence of 22qll deletions in these disorders. Using probes and cosmids from the DiGeorge critical region (DGCR), deletions of 22qll were detected in 83% of DGS and 68% of VCFS patients by DNA dosage analysis, fluorescence in situ hybridisation, or by both methods. Combined with our previously reported patients, deletions have been detected in 88% of DGS and 76% of VCFS patients. The results of prenatal testing for 22qll deletions by FISH in two pregnancies are presented. We conclude that FISH is an efficient and direct method for the detection of 22qll deletions in subjects with features of DGS and VCFS as well as in pregnancies at high risk for a deletion.
Since our initial reports we have evaluated an additional 36 patients presumed to have DGS and 40 patients with the suspected diagnosis of VCFS to determine the prevalence of 22q1 1 deletions in association with these disorders. In addition, we have applied a fluorescence in situ hybridisation (FISH) assay using cosmids from the DiGeorge critical region (DGCR) to detect 22q1 1 deletions directly in patients as well as in pregnancies at risk for a deletion. In this report we describe the results of DNA dosage and FISH studies, discuss the implications for genetic counselling, and describe the application of FISH for the prenatal diagnosis of 22q1 1 microdeletion syndromes.
Materials and methods

PATIENTS
Thirty-six patients with the presumed diagnosis of DGS and four parents of DGS patients with a 22ql 1 deletion were referred to our laboratory for molecular analysis. Forty patients with suspected VCFS were also analysed for evidence of a 22qll deletion. Two cases were studied for prenatal diagnosis. Case 1. One of our previously reported, deletion positive VCFS patients (VCF-10)'9 elected to have an amniocentesis during her second pregnancy. Amniocentesis was performed at 16 weeks' gestation. Cultured amniocytes were obtained for DNA analysis as well as FISH. Case 2. The normal parents of a deletion positive VCFS patient requested that FISH studies be performed to exclude a 22q1 1 deletion in a subsequent pregnancy. This study was performed as an adjunct to routine cytogenetic studies performed for advanced maternal (fig 1D) . FISH indicated hemizygosity at these loci in the remaining parents. Three parents had mild learning disabilities but no history of congenital heart disease, neonatal hypocalcaemia, immune deficiency, or palatal abnormalities (fig lA-C) . In addition to a learning disability, the mother of the fourth proband with DGS had a cleft palate ( fig 1D) . The parent of the child with VCFS also carries the diagnosis of VCFS; she has a cleft palate, learning disorder, and facial dysmorphism consistent with VCFS ( fig 1E) . tic VCFS heart defect study of the affected sib in whom we had previously shown a deletion of both loci. The pregnancy is continuing.
Discussion
Initial studies by our laboratory and others reported an association between DGS, VCFS, and 22q1 1 deletions.5 1619 In these studies over 90% of the patients studied had either cytogenetically visible interstitial deletions or submicroscopic deletions of 22ql 1. We have examined an additional 76 patients with either DGS or VCFS to determine the prevalence of 22ql 1 deletions in these disorders. In the present study, 83% (30 of 36) of presumed DGS patients and 68% (27 of 40) of putative VCFS patients have 22qll deletions. If we include the 14 DGS and 14 VCFS patients we previously reported, then deletions were detected in 88% of patients referred with a diagnosis of DGS and 76% with VCFS.
The percentage of affected patients with a 22ql 1 deletion is less than previously reported. If patients are included in the present study who do not have either DGS or VCFS, we may have underestimated the true prevalence of 22qll deletions in these two groups of patients. It is of interest that the deletion appears to be more frequently detected in patients referred with the diagnosis of DGS. This may reflect the clinician's ability to diagnose DGS accurately in contrast to their ability to recognise VCFS.
The diagnosis of DGS is based on the presence of three findings: a congenital heart defect, hypocalcaemia, and a small or absent thymus. The clinical criteria for establishing a diagnosis of VCFS are not as restricted and it is likely that this study included patients in whom the diagnosis of VCFS was suspected but might not be corroborated. However, we relied on the clinical impressions of the referring geneticists and so the reported frequency of deletions in the population we present in this report may reflect the actual likelihood of detecting a deletion in clinical practice. The high frequency with which deletions were initially detected may reflect the small number of patients studied or the patient sample. The initial sample was derived from fewer clinicians and based on stricter inclusion criteria. Therefore, this study, which examines a large number of patients referred from numerous practising clinicians, provides us with a better estimate of the prevalence of 22ql 1 deletions in patients suspected to have DGS and VCFS.
The majority of patients appear to be deleted for the entire DiGeorge critical region (DGCR). We have not excluded the possibility that the non-deletion patients may have smaller deletions within the DGCR. Studies are in progress to determine whether these patients have deletions internal to the two markers (N25 and R32) used in this study. These disorders may also result from point mutations within critical genes in this region. As genes are identified, the non-deleted patients will be studied for the presence of point mutations.
Alternatively, another locus may be implicated, such as a locus on lOp. There Teratogens, such as retinoic acid and alcohol, and maternal diabetes have been associated with the DiGeorge anomaly.' Molecular studies by our laboratory failed to detect a 22ql1 microdeletion in two infants with DGS born to insulin dependent mothers, supporting the hypothesis that DGS is causally heterogeneous and that this represents a phenocopy of the 22q1 1 microdeletion syndrome. 26 Approximately 8% of the patients studied showed familial transmission of the 22qll deletion. Deletions were detected in seven parents of patients with 22ql 1 deletions, five in this study and two in our previous report. '9 Three parents were also diagnosed as having VCFS. However, three parents had only a learning disability or mild mental retardation and were only ascertained after the birth of an affected child. Such a mild phenotype may reflect which genes in 22ql 1 are deleted. As yet we have not detected a difference in the size of the deletion between numerous affected parents and their affected offspring. However, now that additional probes are available within and flanking the DGCR in 22ql 1, studies are in progress to identify the deletion boundaries in these families to determine if changes in the size of the deletion during meiosis accounts for the observed phenotypic differences. Phenotypic variability may also be explained by parent of origin of the deletion chromosome, genetic background, or in utero environment. We have recently identified highly polymorphic short tandem repeat polymorphisms in the DGCR which will enable us easily to examine the effect of parent of origin on the phenotype. We had previously suggested that molecular and cytogenetic evaluation of the fetus for a 22qll microdeletion should be offered to the parents when a conotruncal heart malformation is detected prenatally.3' Recent studies have shown that 22ql 1 microdeletions occur in 20 to 30% of newborns with non-familial, isolated conotruncal cardiac malformations, including truncus arteriosus, interrupted aortic arch, and tetralogy of Fallot.3233 These findings support our previous recommendation. These findings also suggest that, in addition to subjects with clinical features diagnostic of DGS and VCFS, persons with conotruncal heart defects need to be screened for 22q1 1 microdeletions to determine the aetiology of the disorder, identify other family members at risk for a deletion, and to assess the risk to their offspring.
Subjects with a 22ql 1 deletion have a 50% risk of transmitting the deletion to their offspring and should be offered genetic counselling. Furthermore, since the phenotype of the 22ql 1 microdeletion syndromes is variable, the fetus with a deletion is at risk for the spectrum of malformations seen in both DGS and VCFS. At present we are unable to predict the clinical outcome based on a deletion of the two markers used in the present studies. The correlation between the genotype and phenotype will require a detailed molecular analysis of the deleted region to determine which region or genes specify individual features of the phenotype.
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